UNSPSC 51101918: Artemotil or beta-arteether

This classification denotes an antimalarial agent with the molecular formula C17H28O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XGL7GFB9YI, chemically known as 3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin, decahydro-10-ethoxy-3,6,9-trimethyl-, (3r-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12ar*))- but generally known as arteether, which bears US NIH Compound Identifier 72416. European Medicines Agency schedules Artemotil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00596MIG.

UNSPSC 51101918 Artemotil or beta-arteether, a Commodity code, shows no recent state and local procurement activity aligned with its nominal scope. The two opportunities tagged under this code in the recent activity block—a completed pharmaceutical warehouse piggyback contract for Doxycycline Hyclate and Ciprofloxacin Hydrochloride awarded by the Illinois Department of Public Health, and an open solicitation from Seminole County, Florida for Naloxone and drug deactivation systems—are unrelated to artemotil or beta-arteether products and appear to be misclassified. Neither opportunity involves antimalarial pharmaceutical procurement, and the code itself reports no open solicitations or active buying patterns that reflect the product family it nominally describes.

Without genuine recent opportunities tagged to this code, meaningful characterization of issuing-body mix, geographic concentration, or representative buying patterns is not possible. State and local procurement offices that use this code may do so infrequently or may rely on higher-tier pharmaceutical codes for most related buying. Firms evaluating this code should verify whether state and local procurement offices in their target jurisdictions actually use it for artemotil or beta-arteether procurement, or whether activity has migrated to broader pharmaceutical family or class codes.